文献速递血脂与心血管预防冠心病

ATP柠檬酸裂解酶与脂肪酸合成抑制:叙述性综述

Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition: A Narrative Review.
PubMed 文献 · JAMA Cardiol · 2023-01-01

本文综述ATP柠檬酸裂解酶(ACLY)在糖代谢、胆固醇与脂肪酸合成及炎症中的作用,重点讨论ACLY抑制剂贝派地酸(bempedoic acid)的临床证据。CLEAR Outcomes试验显示贝派地酸在高危他汀不耐受患者中适度降低心血管复合终点及心肌梗死和冠脉血运重建,但未降低卒中、心血管死亡或全因死亡,且痛风与胆石症发生率更高。

要点

  • 贝派地酸在高危他汀不耐受且LDL-C≥100 mg/dL患者中适度降低心血管事件。
  • 贝派地酸未降低卒中、心血管死亡或全因死亡,且痛风与胆石症风险增加。
  • ACLY抑制的额外效应包括抗肿瘤、降甘油三酯和抗炎,正探索新适应症。

核心结论

  • 贝派地酸作为ACLY抑制剂在高危他汀不耐受患者中是安全有效的降LDL-C疗法。
  • CLEAR Outcomes显示贝派地酸适度降低心血管事件,降幅与其LDL-C降低成比例。

研究设计与样本

  • 叙述性综述,总结ACLY抑制剂尤其是贝派地酸的临床数据。
  • CLEAR Outcomes为3期双盲随机安慰剂对照试验,纳入他汀不耐受、LDL-C≥100 mg/dL且有心血管病或高危者。

主要发现

  • 贝派地酸适度降低主要4项心血管复合终点及心肌梗死和冠脉血运重建。
  • 贝派地酸未降低卒中、心血管死亡或全因死亡。
  • 贝派地酸组痛风与胆石症发生率更高,血清肌酐、尿酸和肝酶轻度升高。

关键数值与推荐

  • CLEAR Outcomes纳入标准:他汀不耐受史、血清LDL-C≥100 mg/dL、有心血管病或高危。

临床怎么用

  • 贝派地酸可用于需进一步降LDL-C的高危患者,尤其他汀不耐受者。
  • 使用贝派地酸需关注痛风、胆石症及肌酐、尿酸、肝酶变化。

局限性

  • 本综述为叙述性,未系统检索或定量合并。
  • 多数临床数据集中于贝派地酸,其他ACLY抑制剂证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Adenosine triphosphate citrate lyase (ACLY) is a key regulatory enzyme of glucose metabolism, cholesterol and fatty acid synthesis, and the inflammatory cascade. Bempedoic acid, an ACLY inhibitor, significantly reduces atherogenic lipid markers, including low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol, and apolipoprotein B. Additional effects of ACLY inhibition include antitumor growth; reduction of triglycerides and proinflammatory molecules such as high-sensitivity C-reactive protein; less insulin resistance; reduction of hepatic lipogenesis; and weight loss. OBSERVATIONS: While numerous ACLY inhibitors have been identified, most of the clinical data have focused on bempedoic acid. The Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen (CLEAR) program was a series of phase 3 clinical trials that evaluated its effects on lipid parameters and safety, leading to US Food and Drug Administration approval in 2020. CLEAR Outcomes was a phase 3, double-blind, randomized, placebo-controlled trial in individuals with a history of statin intolerance, serum LDL-C level of 100 mg/dL or higher, and a history of, or at high risk for, cardiovascular disease. Bempedoic acid modestly reduced the primary 4-way cardiovascular composite end point as well as the individual components of myocardial infarction and coronary revascularization but did not reduce stroke, cardiovascular death, or all-cause mortality. Rates of gout and cholelithiasis were higher with bempedoic acid, and small increases in serum creatinine, uric acid, and hepatic-enzyme levels were also observed. CONCLUSIONS AND RELEVANCE: ACLY inhibition with bempedoic acid has been established as a safe and effective therapy in high-risk patients who require further LDL-C lowering, particularly for those with a history of statin intolerance. The recently published CLEAR Outcomes trial revealed modest reductions in cardiovascular events with bempedoic acid, proportional to its LDL-C lowering, in high-risk individuals with statin intolerance and LDL-C levels of 100 mg/dL or higher. The additional effects of ACLY inhibition have prompted a more thorough search for novel ACLY inhibitors for conditions such as cancer, hypertriglyceridemia, chronic inflammation, type 2 diabetes, fatty liver disease, obesity, and metabolic syndrome. Similarly, therapies that reduce fatty acid synthesis are being explored for their use in cardiometabolic conditions.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Duarte Lau F, Giugliano RP. Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition: A Narrative Review. JAMA Cardiol. 2023. PMID: 37585218. doi:10.1001/jamacardio.2023.2402

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。